Welcome to our dedicated page for ALISR news (Ticker: ALISR), a resource for investors and traders seeking the latest updates and insights on ALISR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ALISR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ALISR's position in the market.
Calisa Acquisition Corp (Nasdaq: ALISU / ALIS) priced an initial public offering of 6,000,000 units at $10.00 per unit, for total gross proceeds of $60,000,000. The units will begin trading on the Nasdaq Global Market on October 22, 2025 under the ticker ALISU. Each unit contains one ordinary share and one right to receive 0.1 ordinary share upon completion of an initial business combination.
Once separated, ordinary shares and rights are expected to trade as ALIS and ALISR. The offering includes a 45-day underwriter option to purchase up to 900,000 additional units. The company is a Cayman exempt blank check company formed to pursue a business combination and intends to focus its search on businesses throughout Asia. A registration statement became effective on October 20, 2025.
